Literature DB >> 23496764

A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation.

Carolyn Bentley1, Stefanie S Jurinka, Noelyn M Kljavin, Steffan Vartanian, Sree R Ramani, Lino C Gonzalez, Kebing Yu, Zora Modrusan, Pan Du, Richard Bourgon, Richard M Neve, David Stokoe.   

Abstract

The mutant forms of KRas, NRas and HRas drive the initiation and progression of a number of human cancers, but less is known about the role of WT (wild-type) Ras alleles and isoforms in cancer. We used zinc-finger nucleases targeting HRas and NRas to modify both alleles of these genes in the mutant KRas-driven Hec1A endometrial cancer cell line, which normally expresses WT copies of these genes. The disruption of either WT isoform of Ras compromised growth-factor-dependent signalling through the ERK (extracellular-signal-regulated kinase) pathway. In addition, the disruption of HRas hindered the activation of Akt and subsequent downstream signalling. This was associated with decreased proliferation, increased apoptosis and decreased anchorage-independent growth in the HRas-disrupted cells. However, xenograft tumour growth was not significantly affected by the disruption of either NRas or HRas. As expected, deleting the mutant allele of KRas abolished tumour growth, whereas deletion of the remaining WT copy of KRas increased the tumorigenic properties of these cells; deleting a single copy of either HRas or NRas did not mimic this effect. The present study demonstrates that the WT copies of HRas, NRas and KRas play unique roles in the context of mutant KRas-driven tumours.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23496764     DOI: 10.1042/BJ20121578

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  23 in total

Review 1.  How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization.

Authors:  Ethan J Brock; Kyungmin Ji; John J Reiners; Raymond R Mattingly
Journal:  Mini Rev Med Chem       Date:  2016       Impact factor: 3.862

2.  Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer.

Authors:  Craig M Bielski; Mark T A Donoghue; Mayur Gadiya; Aphrothiti J Hanrahan; Helen H Won; Matthew T Chang; Philip Jonsson; Alexander V Penson; Alexander Gorelick; Christopher Harris; Alison M Schram; Aijazuddin Syed; Ahmet Zehir; Paul B Chapman; David M Hyman; David B Solit; Kevin Shannon; Sarat Chandarlapaty; Michael F Berger; Barry S Taylor
Journal:  Cancer Cell       Date:  2018-11-01       Impact factor: 31.743

Review 3.  Ras and Rap1: A tale of two GTPases.

Authors:  Seema Shah; Ethan J Brock; Kyungmin Ji; Raymond R Mattingly
Journal:  Semin Cancer Biol       Date:  2018-04-03       Impact factor: 15.707

Review 4.  Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design.

Authors:  Jonathan M L Ostrem; Kevan M Shokat
Journal:  Nat Rev Drug Discov       Date:  2016-07-29       Impact factor: 84.694

Review 5.  Small-molecule modulation of Ras signaling.

Authors:  Jochen Spiegel; Philipp M Cromm; Gunther Zimmermann; Tom N Grossmann; Herbert Waldmann
Journal:  Nat Chem Biol       Date:  2014-06-15       Impact factor: 15.040

6.  Genomic classification of the RAS network identifies a personalized treatment strategy for lung cancer.

Authors:  Nader N El-Chaar; Stephen R Piccolo; Kenneth M Boucher; Adam L Cohen; Jeffrey T Chang; Philip J Moos; Andrea H Bild
Journal:  Mol Oncol       Date:  2014-05-20       Impact factor: 6.603

Review 7.  Mutant allele specific imbalance in oncogenes with copy number alterations: Occurrence, mechanisms, and potential clinical implications.

Authors:  Chih-Chieh Yu; Wanglong Qiu; Caroline S Juang; Mahesh M Mansukhani; Balazs Halmos; Gloria H Su
Journal:  Cancer Lett       Date:  2016-10-08       Impact factor: 8.679

8.  RAS Promotes Proliferation and Resistances to Apoptosis in Meningioma.

Authors:  Chunling Jiang; Tao Song; Jingao Li; Fan Ao; Xiaochang Gong; Yicheng Lu; Chenran Zhang; Liangyu Chen; Yunhui Liu; Hua He; Ouping Huang
Journal:  Mol Neurobiol       Date:  2016-03-28       Impact factor: 5.590

Review 9.  Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer.

Authors:  Alice C Fan; Jennifer J O'Rourke; Dave R Praharaj; Dean W Felsher
Journal:  Expert Opin Investig Drugs       Date:  2013-08-12       Impact factor: 6.206

10.  Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation.

Authors:  Erin Sheffels; Nancy E Sealover; Chenyue Wang; Do Hyung Kim; Isabella A Vazirani; Elizabeth Lee; Elizabeth M Terrell; Deborah K Morrison; Ji Luo; Robert L Kortum
Journal:  Sci Signal       Date:  2018-09-04       Impact factor: 8.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.